Group 1 - Repligen reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.41 per share, and up from $0.33 per share a year ago, representing an earnings surprise of 7.32% [1] - The company posted revenues of $167.55 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.10%, compared to $155.74 million in the same quarter last year [2] - Over the last four quarters, Repligen has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Repligen shares gaining about 4.7% year-to-date, compared to the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $163.53 million, and for the current fiscal year, it is $1.71 on revenues of $695.77 million [7] - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8]

Revenue and Growth - Fourth quarter revenue was $168 million, representing a 13% growth excluding COVID-related revenue[6] - Full year revenue for 2024 reached $634 million, compared to $632 million in 2023[7] - Orders in Q4 outpaced revenue by 6%, with sequential increases of 11% in orders and 8% in revenues[6] - The company provided guidance for 2025, expecting total reported revenue growth of 8% to 12% and non-COVID revenue growth of 10% to 14%[10] Profit and Loss - Q4 GAAP gross profit was $39 million, with an adjusted gross profit of $85 million[7] - Q4 GAAP net loss was $(34) million, while adjusted net income was $25 million[12] - The company reported a GAAP gross margin of 23.2% for Q4 2024, down from 47.1% in Q4 2023[9] - Net loss for Q4 2024 was $33.9 million, compared to a net loss of $16.5 million in Q4 2023[22] - Adjusted net income for the year ended December 31, 2024, was $88.8 million, down from $93.2 million in 2023[26] Expenses - Research and development expenses for Q4 2024 were $11.7 million, up from $10.3 million in Q4 2023[22] - Selling, general and administrative expenses increased to $60.5 million in Q4 2024 from $57.6 million in Q4 2023[22] - The company reported an adjusted income from operations of $25.0 million for Q4 2024, compared to $29.7 million in Q4 2023[25] - Research and development (R&D) expenses (GAAP) for the year ended December 31, 2024, were $43,200 thousand, slightly up from $42,722 thousand in 2023, with adjusted R&D expenses (Non-GAAP) of $42,266 thousand, down from $42,611 thousand[30] - Selling, general and administrative (SG&A) expenses (GAAP) for the year ended December 31, 2024, were $263,368 thousand, compared to $218,584 thousand in 2023, while adjusted SG&A expenses (Non-GAAP) were $195,621 thousand, up from $179,607 thousand[31] Cash and Assets - Cash and cash equivalents at the end of 2024 were $757 million, up from $751 million at the end of 2023[9] - Cash, cash equivalents, and marketable securities totaled $757.4 million as of December 31, 2024, compared to $751.3 million at the end of 2023[22] - Total assets decreased slightly to $2.83 billion as of December 31, 2024, from $2.83 billion at the end of 2023[22] Guidance and Projections - The company anticipates a GAAP net income guidance for the year ending December 31, 2025, in the range of $51,000 thousand to $56,000 thousand, with adjusted net income (Non-GAAP) guidance of $95,000 thousand to $100,000 thousand[32] - The guidance for diluted earnings per share (GAAP) for the year ending December 31, 2025, is projected between $0.90 and $0.99, with adjusted diluted earnings per share (Non-GAAP) guidance of $1.67 to $1.76[33] Restructuring and Strategic Planning - The company recorded pre-tax costs of $46.9 million and $32.2 million in 2024 and 2023, respectively, related to restructuring activities aimed at streamlining operations[36] - The company reviewed its manufacturing strategy and footprint as part of the 2024 annual strategic planning and budget session[40] - Future demand and product mix projections were revised during the annual strategic planning and budget sessions in 2024[39] Inventory and Charges - Non-cash inventory write-off in 2024 resulted from discontinuing certain product SKUs and evaluating inventory positions amid turbulent market conditions[39] - In Q4 2024, non-cash charges included write-off of abandoned equipment related to unneeded capacity for a specific product line, with plans to reallocate factory space[40] - Incremental stock compensation expense of $16 million for Q4 2024 and $22.362 million for the full year was due to the CEO's transition to Executive Chair[41] - Foreign currency adjustments on intercompany loans amounted to ($4.883 million) for Q4 2024 and ($5.509 million) for the full year[41] - Amortization of milestone payments was $28 million for Q4 2024 and 2023, and $112 million for the full year[41] - Accelerated depreciation related to the restructuring plan was $19 million for the full year 2024[41] Market Conditions - The company proactively secured materials during the pandemic to meet accelerated demand, impacting inventory write-offs[38]

Core Insights - Repligen Corporation reported a total revenue of $168 million for Q4 2024, reflecting a 1% increase compared to Q4 2023, and a full-year revenue of $634 million, which is flat compared to the previous year [5][20][23] - The company experienced a 13% revenue growth in Q4 2024 when excluding COVID-related revenue, with total orders outpacing sales by 6% [2][5] - Repligen provided financial guidance for 2025, expecting total reported revenue to be between $685 million and $710 million, representing an 8% to 12% growth [10][9] Financial Performance - Q4 2024 GAAP gross profit was $39 million, down from $78 million in Q4 2023, while adjusted gross profit was $85 million compared to $87 million in the prior year [6][4] - The company reported a GAAP net loss of $34 million for Q4 2024, compared to a loss of $16 million in Q4 2023, with adjusted net income of $25 million versus $27 million [6][21] - For the full year 2024, GAAP net loss was $26 million, compared to a profit of $36 million in 2023, while adjusted net income was $89 million, down from $93 million [6][21] Business Highlights - Orders for Contract Development and Manufacturing Organizations (CDMOs) and capital equipment increased approximately 15% and 30% sequentially, indicating a recovery in these markets [6][2] - The company completed the acquisition of Tantti Laboratory Inc, enhancing its chromatography offerings [6][2] - Repligen launched AVIPure dsRNA resin, the first affinity resin for the removal of double-stranded RNA, targeting mRNA-based therapeutics and vaccines [6][2] Margin Summary - Q4 2024 GAAP gross margin was 23.2%, significantly lower than 47.1% in Q4 2023, while adjusted gross margin was 50.7%, down from 52.5% [7] - The operating (EBIT) margin for Q4 2024 was -21.8%, compared to 5.9% in Q4 2023, while the adjusted operating margin was 14.9%, down from 17.8% [7] Cash Position - As of December 31, 2024, cash and cash equivalents stood at $757 million, slightly up from $751 million at the end of 2023 [7]

Core Points - Repligen Corporation will report its fourth quarter 2024 financial results on February 20, 2025, with a press release issued before market opening [1] - A conference call will be held at 8:30 a.m. ET on the same day to discuss business updates and financial results for the three- and twelve-month periods ending December 31, 2024 [1] Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems for manufacturing biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]

Company Overview - Repligen (RGEN) shares increased by 3.7% to $174.24 in the last trading session, with a notable trading volume indicating strong investor interest [1] - The company specializes in advanced bioprocessing technologies and solutions for large biopharmaceutical companies and contract manufacturing organizations [2] Financial Performance - Repligen is expected to report quarterly earnings of $0.41 per share, reflecting a year-over-year increase of 24.2% [3] - Revenue projections for the upcoming quarter stand at $167.72 million, which is a 7.7% increase compared to the same quarter last year [3] - However, the consensus EPS estimate has been revised down by 1.3% over the last 30 days, which may impact future stock price appreciation [4] Industry Context - Repligen is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Exelixis (EXEL), experienced a 0.4% decline in its last trading session [4] - Exelixis has a consensus EPS estimate of $0.50, representing a significant year-over-year change of 51.5% [5]

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live webcast of the conference presentation will be accessible through Repl ...

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in co ...

It has been about a month since the last earnings report for Repligen (RGEN) . Shares have added about 3.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Repligen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Repligen’s Q3 Earnings & Revenues Surpass EstimatesRe ...

Core Insights - Repligen Corporation has published its 2023 Corporate Sustainability Report themed "Advancing Impacts," highlighting progress in sustainability across six key areas [1][2] - The report includes disclosures aligned with major reporting frameworks such as GRI, SASB, UN SDGs, and TCFD [1] Sustainability Highlights - Transitioned to 100% renewable electricity at 13 out of 18 manufacturing sites, accounting for 88% of global consumption [3] - Increased the percentage of women in management roles from 27% in 2022 to 29% in 2023 [3] - Achieved a 68% reduction in Scope 2 emissions from 2022 to 2023 [3] - Realized a 60% increase in productivity savings through the Repligen Performance System compared to 2022 [3] - Committed to achieving net-zero emissions by 2050 in alignment with the Science Based Targets initiative [3]

Repligen Corporation (NASDAQ:RGEN) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital ...